Search research articles
Contact Us
Filters
Showing results (11-20 of 109) with videos related to
Page
of 11
Sort By:
Methods in Molecular Biology (Clifton, N.J.)
|
October 1, 2011
A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1
Wolfgang Reindl, Klaus Strebhardt, Thorsten Berg
Cancers
|
June 2, 2021
Targeting CDK9 for Anti-Cancer Therapeutics
Ranadip Mandal, Sven Becker, Klaus Strebhardt
Oncogene
|
January 11, 2005
Polo-like kinases and oncogenesis
Frank Eckerdt, Juping Yuan, Klaus Strebhardt
Expert Opinion on Drug Discovery
|
September 30, 2014
Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery
Klaus Strebhardt, Sven Becker, Yves Matthess
Molecular & Cellular Oncology
|
December 8, 2018
The role of PLK1 in cancer exhibiting chromosomal instability
Klaus Strebhardt, Monika Raab, Mourad Sanhaji
Analytical Biochemistry
|
September 17, 2008
A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1
Wolfgang Reindl, Klaus Strebhardt, Thorsten Berg
Anticancer Research
|
March 14, 2007
The biological relevance of FHL2 in tumour cells and its role as a putative cancer target
Kai Kleiber, Klaus Strebhardt, Bernd T Martin
BMC Research Notes
|
December 8, 2018
Immune adaptor protein SKAP1 (SKAP-55) forms homodimers as mediated by the N-terminal region
Monika Raab, Klaus Strebhardt, Christopher E Rudd
Scientific Reports
|
July 20, 2019
Immune adaptor SKAP1 acts a scaffold for Polo-like kinase 1 (PLK1) for the optimal cell cycling of T-cells
Monika Raab, Klaus Strebhardt, Christopher E Rudd
Analytical Biochemistry
|
September 1, 2009
Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3
Wolfgang Reindl, Martin Gräber, Klaus Strebhardt, et al.
Page
of 11
Search research articles
Search
Showing results (11-20 of 109) with videos related to
Sort By:
Page
of 11
Methods in Molecular Biology (Clifton, N.J.)
|
October 1, 2011
A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1
Wolfgang Reindl, Klaus Strebhardt, Thorsten Berg
Cancers
|
June 2, 2021
Targeting CDK9 for Anti-Cancer Therapeutics
Ranadip Mandal, Sven Becker, Klaus Strebhardt
Oncogene
|
January 11, 2005
Polo-like kinases and oncogenesis
Frank Eckerdt, Juping Yuan, Klaus Strebhardt
Expert Opinion on Drug Discovery
|
September 30, 2014
Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery
Klaus Strebhardt, Sven Becker, Yves Matthess
Molecular & Cellular Oncology
|
December 8, 2018
The role of PLK1 in cancer exhibiting chromosomal instability
Klaus Strebhardt, Monika Raab, Mourad Sanhaji
Analytical Biochemistry
|
September 17, 2008
A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1
Wolfgang Reindl, Klaus Strebhardt, Thorsten Berg
Anticancer Research
|
March 14, 2007
The biological relevance of FHL2 in tumour cells and its role as a putative cancer target
Kai Kleiber, Klaus Strebhardt, Bernd T Martin
BMC Research Notes
|
December 8, 2018
Immune adaptor protein SKAP1 (SKAP-55) forms homodimers as mediated by the N-terminal region
Monika Raab, Klaus Strebhardt, Christopher E Rudd
Scientific Reports
|
July 20, 2019
Immune adaptor SKAP1 acts a scaffold for Polo-like kinase 1 (PLK1) for the optimal cell cycling of T-cells
Monika Raab, Klaus Strebhardt, Christopher E Rudd
Analytical Biochemistry
|
September 1, 2009
Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3
Wolfgang Reindl, Martin Gräber, Klaus Strebhardt, et al.
Page
of 11